Scholar Rock Holding Corporation shares surge 15.64% intraday after FDA grants priority review to apitegromab for SMA treatment and grants stock awards to new employees.

miércoles, 20 de agosto de 2025, 11:49 am ET1 min de lectura
SRRK--
Scholar Rock Holding Corporation surged 15.64% intraday, following the announcement of stock awards to 64 new employees and FDA's priority review for apitegromab treatment for SMA, with plans to expand in Europe.

Scholar Rock Holding Corporation shares surge 15.64% intraday after FDA grants priority review to apitegromab for SMA treatment and grants stock awards to new employees.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios